High-throughput, high-titer CHO production of miniproteins with high yields and low endotoxin levels, surpassing traditional E. coli production methods.
End-to-End, Multi-Species In Vivo Pharmacology
With a track record of over 800 successful projects, we provide end-to-end, multi-species in vivo pharmacology services spanning PKPD, efficacy, toxicology, and histology studies. With deep expertise in key therapeutic areas, such as oncology, autoimmune diseases, and inflammatory disorders, we offer seamless support from preclinical research through IND filing and beyond.
Tumor-Luciferase Reporter
Efficacy Study
• Mouse, rat and monkey
Organ Distribution Analysis
0
3
6
9 12 B IB 21 M 27
• PK, PD, IHC • In vivo imaging and biodistribution • In vitro & ex vivo biomarker and MOA studies
Days Post Grouping
Rodent PK Study
100000
- Abl 10 mg/kg - Ab2 10 mg/kg - Ab3 10 mg/kg
E
10000
• Autoimmune diseases • Rare diseases • Metabolic diseases
• Syngeneic • Humanized/WT • CDX; CDX/PBMC • GVHD
bl)
1000
100
u
10
0.1
12
15
Time (day)
Key Features of NHP PK/PD/Tox Services
• Monkeys scheduled within 7 days • Highly customized assay development
• Adaptable to accommodate specific client requirements • Expert data intepretation with proactive troubleshooting • Total timeline of 6-11 weeks
About WuXi Biologics CRO Services
WuXi Biologics is a leading global CRDMO, with the R represented by our premium-quality CRO Services. With expertise in diverse drug modalities, we deliver comprehensive research services, including antibody discovery, protein production and engineering, and in vitro/in vivo testing, to seamlessly advance our clients' molecules from concept to CMC development.
WuXi Biologics Global Solution Provider�-.,
Drug Development Expertise Empowering Research Services for Biologics
https://www.wuxibiologics.com/cro-services/ I PS_Marketing@wuxibiologics.com
Page 1 Page 2 Page 3 Page 4Powered by FlippingBook